Johnson & Johnson/$JNJ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Ticker
$JNJ
Sector
Primary listing
NYSE
Employees
138,100
Headquarters
Website
JNJ Metrics
BasicAdvanced
$454B
20.21
$9.33
0.39
$5.08
2.76%
Price and volume
Market cap
$454B
Beta
0.39
52-week high
$189.78
52-week low
$140.68
Average daily volume
8.5M
Dividend rate
$5.08
Financial strength
Current ratio
1.006
Quick ratio
0.678
Long term debt to equity
49.998
Total debt to equity
64.686
Dividend payout ratio (TTM)
53.34%
Interest coverage (TTM)
30.44%
Profitability
EBITDA (TTM)
30,255
Gross margin (TTM)
68.40%
Net profit margin (TTM)
25.00%
Operating margin (TTM)
25.36%
Effective tax rate (TTM)
17.14%
Revenue per employee (TTM)
$660,000
Management effectiveness
Return on assets (TTM)
7.61%
Return on equity (TTM)
30.21%
Valuation
Price to earnings (TTM)
20.21
Price to revenue (TTM)
5.005
Price to book
5.81
Price to tangible book (TTM)
-23.31
Price to free cash flow (TTM)
27.69
Free cash flow yield (TTM)
3.61%
Free cash flow per share (TTM)
6.812
Dividend yield (TTM)
2.69%
Forward dividend yield
2.76%
Growth
Revenue change (TTM)
4.68%
Earnings per share change (TTM)
-39.59%
3-year revenue growth (CAGR)
0.91%
10-year revenue growth (CAGR)
2.34%
3-year earnings per share growth (CAGR)
10.74%
10-year earnings per share growth (CAGR)
5.10%
3-year dividend per share growth (CAGR)
5.21%
10-year dividend per share growth (CAGR)
5.82%
What the Analysts think about JNJ
Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.
Bulls say / Bears say
J&J beat Q2 2025 profit estimates with adjusted EPS of $2.77 (vs. $2.68 expected), driven by Darzalex oncology sales of $3.54 billion and a 6.1% medtech revenue increase, leading to full‐year sales guidance raised to $93.2–93.6 billion (Reuters)
The FDA approved Imaavy for generalized myasthenia gravis on April 30, 2025, covering over 90% of U.S. patients and targeting peak annual sales above $5 billion, bolstering J&J’s immunology portfolio (Reuters)
On September 9, 2025, the FDA approved Inlexzo (TAR-200) for high‐risk non–muscle invasive bladder cancer, demonstrating over 82% patient response at three months and providing a non‐surgical treatment for ~75% of bladder cancer cases (Reuters)
A U.S. judge rejected J&J’s $10 billion proposal to settle talc litigation on April 1, 2025, forcing the company to defend against over 60,000 claims in court and prolonging legal uncertainty (Reuters)
A July 29, 2025 Massachusetts jury awarded $42.6 million to a mesothelioma plaintiff who alleged J&J’s talc contained asbestos, highlighting ongoing exposure to large punitive verdicts across 63,000+ talc suits (Reuters)
J&J is under a federal criminal investigation over its disclosures about talc safety, adding a layer of regulatory risk and potential penalties to its prolonged litigation saga (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
JNJ Financial Performance
Revenues and expenses
JNJ Earnings Performance
Company profitability
JNJ News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Johnson & Johnson stock?
Johnson & Johnson (JNJ) has a market cap of $454B as of October 06, 2025.
What is the P/E ratio for Johnson & Johnson stock?
The price to earnings (P/E) ratio for Johnson & Johnson (JNJ) stock is 20.21 as of October 06, 2025.
Does Johnson & Johnson stock pay dividends?
Yes, the Johnson & Johnson (JNJ) stock pays dividends to shareholders. As of October 06, 2025, the dividend rate is $5.08 and the yield is 2.76%. Johnson & Johnson has a payout ratio of 53.34% on a trailing twelve-month basis.
When is the next Johnson & Johnson dividend payment date?
The next Johnson & Johnson (JNJ) dividend payment date is unconfirmed.
What is the beta indicator for Johnson & Johnson?
Johnson & Johnson (JNJ) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.